Pharmacokinetics, safety, and efficacy of cedirogant from phase I studies in healthy participants and patients with chronic plaque psoriasis
Abstract Cedirogant is an inverse agonist of retinoic acid‐related orphan receptor gamma thymus (RORγt) developed for the treatment of moderate to severe chronic plaque psoriasis. Here, we report the results from two phase I studies in which the pharmacokinetics (PK), safety, and efficacy of cedirog...
Saved in:
Main Authors: | Mohamed‐Eslam F. Mohamed (Author), Yuli Qian (Author), Ronilda D'Cunha (Author), Teresa Sligh (Author), Laura K. Ferris (Author), Ann Eldred (Author), Gweneth F. Levy (Author), Shuai Hao (Author), Shashikanth Gannu (Author), David G. Rizzo (Author), Wei Liu (Author), Sasha Jazayeri (Author), Howard Sofen (Author), Roberto Carcereri De Prati (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2024-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Annular scaly plaques with peripheral pustules
by: Lisa Faye Fronek, DO, et al.
Published: (2022) -
Risankizumab: Mechanism of action, clinical and translational science
by: Yinuo Pang, et al.
Published: (2024) -
Comedonal Plaque on the Face
by: Haifa Mkhinini, et al.
Published: (2023) -
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials
by: Neil J. Korman, et al.
Published: (2024) -
A Congenital Plaque-Like Myofibroblastic Tumor
by: Haifa Mkhinini, et al.
Published: (2023)